34 results
8-K/A
EX-99.1
RNAC
Cartesian Therapeutics Inc
23 Jan 24
Independent Auditor’s Report
4:05pm
with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under
8-K
EX-99.3
RNAC
Cartesian Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
8:45am
are steadfast in our commitment to delivering meaningful new therapies to patients with autoimmune diseases in areas of high unmet need and look forward
DEFA14A
wn46m4z0fg0gv0s
13 Nov 23
Additional proxy soliciting materials
9:06am
8-K
EX-10.1
avhln53e
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-2.1
xpjht4oi tjpvsa
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-99.2
5yu5q6rt
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-3.2
k5bwr9
22 Aug 22
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
EX-99.1
11br5q6q8f q1w
13 Jun 22
Selecta Biosciences Announces Partnership Advancements
8:00am
DEFR14A
f6dwi s2ib89
3 May 22
Revised proxy
2:15pm
PRE 14A
t1v6k ckcd8o3b2
22 Apr 22
Preliminary proxy
3:08pm
8-K
EX-3.2
ls4gjhlkc81xi0z8rdj
30 Sep 21
Amendments to Articles of Incorporation or Bylaws
8:00am